Marijuana Abuse Clinical Trial
Official title:
Parallel Groups Study of Divalproex Sodium (Depakote) for Irritable, Explosive Adults & Adolescents
The purpose of this study is to compare the effectiveness of divalproex sodium (Depakote) versus placebo in treating disruptive behavior disorder and explosive tempers in adolescents and adults.
Disruptive behavior disorders among children and adolescents are readily diagnosed; however,
few individuals with such disorders receive drug treatment. Depakote is a mood stabilizing
medication that may be beneficial in treating individuals with disruptive behavior disorders.
The purpose of this study is to examine the effectiveness of Depakote in reducing temper
outbursts and improving mood in individuals with disruptive behavior disorders. In addition,
this study will determine the safety and effectiveness of Depakote in treating individuals
with substance disorders who also have disruptive behavior disorders.
This study will last 6 weeks. Participants will be randomly assigned to receive treatment
with Depakote or placebo. Medication will be given in a single evening dose if tolerated;
otherwise, medication will be given twice per day. Participants will be assigned to a
fixed-flexible dosing schedule and dosages will increase based on weight. All participants
will attend weekly psychotherapy and family counseling sessions throughout the study.
Participants who are substance abusers will also receive substance abuse counseling. Weekly
study visits will include a physical exam, blood collection, and drug tests. Teachers and
guidance counselors will be contacted to assess the participant's behavior from week to week.
Some participants will complete a follow-up study, in which they will take part in phone
interviews.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01539525 -
Screening to Augment Referral to Treatment- Project START
|
Phase 2 | |
Completed |
NCT00158249 -
Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals
|
Phase 2 | |
Completed |
NCT00842985 -
Dronabinol Interactions in Humans
|
N/A | |
Completed |
NCT00484302 -
Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis
|
N/A | |
Completed |
NCT00227903 -
Therapeutic Substance Abuse Treatment in Pregnancy - 1
|
Phase 2 | |
Completed |
NCT00227864 -
A Brief Marijuana Intervention for Adolescent Women - 1
|
Phase 3 | |
Completed |
NCT00218478 -
Evaluating Responses to Drug-Related Cues Versus Neutral Cues to Understand the Effects of Marijuana Craving - 1
|
Phase 1 | |
Completed |
NCT00249509 -
Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals
|
Phase 2 | |
Completed |
NCT03717272 -
Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects
|
Phase 2 | |
Completed |
NCT00142961 -
Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder
|
Phase 2 | |
Terminated |
NCT02102230 -
CBT-I for Cannabis Use
|
N/A | |
Completed |
NCT00580671 -
Treatment for Adolescent Marijuana Abuse
|
N/A | |
Completed |
NCT00360269 -
Atomoxetine Treatment for ADHD and Marijuana Dependence
|
Phase 2 | |
Completed |
NCT00227916 -
Motivational Interviews for Incarcerated Teens - 1
|
N/A | |
Completed |
NCT03154567 -
Effects of Stress and Drug-cue Exposure (SCM)
|
Phase 1 | |
Active, not recruiting |
NCT05322941 -
Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)
|
Phase 2 | |
Completed |
NCT02797990 -
Conflict Between Maternal Autonomy and Child Health in Substance-use
|
N/A | |
Completed |
NCT01762696 -
A Real-time, Contextual Intervention Using Mobile Technology to Reduce Marijuana Use in Youth
|
N/A | |
Completed |
NCT03154580 -
Marijuana Cue-Reactivity & Seeking Behavior in Regular Cannabis Users
|
Phase 1 | |
Completed |
NCT00217971 -
Dronabinol Treatment for Marijuana Addiction
|
Phase 2 |